Quick Summary
This study tested whether a supplement called oxaloacetate could help reduce fatigue in ME/CFS and Long COVID patients. Over 6 weeks, patients taking oxaloacetate showed significant improvements in both mental and physical fatigue—with ME/CFS patients improving by 22–33% depending on dose, and Long COVID patients improving by up to 47%—compared to expected placebo improvements of about 6%.
Why It Matters
With no FDA-approved treatments for ME/CFS fatigue and millions suffering from persistent post-COVID fatigue, this study offers preliminary evidence for a potential low-risk nutritional intervention. The dose-dependent response pattern and improvements substantially exceeding historical placebo suggest oxaloacetate warrants further rigorous investigation in this severely understudied patient population.
Observed Findings
What the study reports it measured.
- ME/CFS patients receiving 500 mg BID showed 21.7% fatigue reduction; those receiving 1,000 mg BID showed 27.6% reduction; and those receiving 1,000 mg TID showed 33.3% reduction (dose-dependent response).
- Long COVID patients showed fatigue reductions up to 46.8% over 6 weeks.
- Both physical and mental fatigue components improved significantly in both patient populations compared to baseline (P < 0.005).
- Improvement exceeded historical placebo control average of 5.9%.
Inferred Conclusions
What the authors interpret from those results.
- Oxaloacetate may effectively reduce pathological fatigue in both ME/CFS and Long COVID patients, with higher doses associated with greater benefit.
- The medication-like efficacy combined with its classification as a nutritional supplement suggests it could bridge an important treatment gap for millions of patients.
- Further rigorous randomized controlled trials are warranted to confirm efficacy and establish optimal dosing.
Remaining Questions
- Does oxaloacetate reduce fatigue through specific biological mechanisms (e.g., ATP production, mitochondrial function) or through placebo/expectancy effects in this open-label design?
- What is the optimal effective dose, and does tolerability or safety change at higher doses over longer treatment periods?
- Do improvements persist beyond 6 weeks, and are there responder/non-responder phenotypes based on ME/CFS disease duration, severity, or biomarkers?
- How do results compare in a properly blinded, randomized controlled trial with concurrent placebo controls?
What This Study Does Not Prove
This study does not prove oxaloacetate is effective because it lacks a concurrent randomized control group receiving placebo in parallel—relying instead on historical placebo data introduces bias and cannot control for concurrent environmental or temporal factors. The open-label design is subject to placebo response and expectancy effects, and the study cannot establish whether oxaloacetate specifically alleviates fatigue through a biological mechanism or through other unmeasured factors.
Explore further
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Cite this study
The first block is for the primary paper and is the citation you should use in research work. The atlas-snapshot line only applies if you are specifically referring to this atlas’s reading of the paper on the date shown.
Primary citation
Cash, Alan & Kaufman, David Lyons (2022). Oxaloacetate Treatment For Mental And Physical Fatigue In Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long-COVID fatigue patients: a non-randomized controlled clinical trial.. Journal of translational medicine. https://doi.org/10.1186/s12967-022-03488-3
BibTeX
@article{mecfsatlas-cash-2022-oxaloacetate-treatment,
author = {Cash, Alan and Kaufman, David Lyons},
title = {Oxaloacetate Treatment For Mental And Physical Fatigue In Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long-COVID fatigue patients: a non-randomized controlled clinical trial.},
journal = {Journal of translational medicine},
year = {2022},
doi = {10.1186/s12967-022-03488-3},
note = {PubMed: 35764955},
url = {https://www.mecfsatlas.com/evidence/cash-2022-oxaloacetate-treatment},
}Atlas snapshot reference
ME/CFS Atlas. Generator v1 / Scanner v1.4 / policy v0.1. Accessed 2026-11-15. https://www.mecfsatlas.com/evidence/cash-2022-oxaloacetate-treatment
Contribute
Private, reviewed by a human. Not a public comment thread.